Research programme: antibacterials - Cangene

Drug Profile

Research programme: antibacterials - Cangene

Alternative Names: PEP 35

Latest Information Update: 28 Feb 2014

Price : $50

At a glance

  • Originator Cangene Corporation
  • Developer Emergent BioSolutions
  • Class Antibodies; Monoclonal antibodies; Peptides
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Burkholderia infections; Postoperative infections

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 18 Jul 2008 Preclinical development is ongoing
  • 18 Jul 2008 Preclinical trials in Postoperative infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top